Patents by Inventor Matthias Machacek

Matthias Machacek has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR LONG ACTING MOLECULES
    Publication number: 20160297854
    Abstract: The invention relates, in part, to compositions and methods that utilize a peptide tag that binds to hemagglutanin (HA). The HA tag can be linked to a molecule such as a protein or nucleic acid which, when administered to the eye, results in an increase in ocular half-life and/or mean residence time, and or a decrease in ocular clearance of the protein or nucleic acid. The invention also encompasses methods for treating ocular disease, including retinal vascular disease, by administering a protein or nucleic acid linked to an HA peptide tag.
    Type: Application
    Filed: June 17, 2016
    Publication date: October 13, 2016
    Applicant: Novartis AG
    Inventors: Joy GHOSH, Michael ROGUSKA, Andrew Anh NGUYEN, Thomas PIETZONKA, Matthias MACHACEK, Andrei GOLOSOV
  • METHODS OF TREATING RHEUMATOID ARTHRITIS USING IL-17 ANTAGONISTS
    Publication number: 20130209480
    Abstract: The disclosure relates to novel regimens for treating an inflammatory arthritis, e.g., rheumatoid arthritis (RA) patients, e.g., high risk RA patients, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., IL-17 binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof, e.g., secukinumab) or IL-17 receptor binding molecule (e.g., IL-17 antibody or antigen binding fragment thereof).
    Type: Application
    Filed: November 4, 2011
    Publication date: August 15, 2013
    Applicant: Novartis AG
    Inventors: Shephard Mpofu, Hanno Richards, Karthinathan Thangavelu, Matthias Machacek
  • METHODS OF TREATING PSORIASIS USING IL-17 ANTAGONISTS
    Publication number: 20130202610
    Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.
    Type: Application
    Filed: October 7, 2011
    Publication date: August 8, 2013
    Applicant: Novartis AG
    Inventors: Achim Guettner, Matthias Machacek, Charis Papavassillis, Oliver Sander